NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical…
According to GlobalData, NewAmsterdam’s obicetrapib is expected to be the most promising agent to launch in the dyslipidemia…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
dyslipidemia
Long road ahead for non-statin therapies in Australia dyslipidemia treatment space: GlobalData
According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in…